uniQure shares surge as FDA stance appears to reopen a near-term filing path for AMT-130

uniQure N.V. (QURE) is up 72.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is a company update indicating a clearer path to a U.S. Biologics License Application (BLA) submission for AMT-130 in Huntington’s disease, following recent FDA dialogue. With the stock previously pressured by FDA feedback that implied a longer, Phase III-style path, any perceived “green light” to file on existing data can meaningfully re-rate expectations.

Details:

uniQure’s investor site shows a new June 17, 2026 press release titled “uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease,” signaling a material regulatory development.

Public reporting tied the move to comments from a recent Type B FDA meeting where the agency indicated the company’s 3-year analysis could be acceptable for a BLA submission, with uniQure targeting a filing in Q3 2026.

Earlier in 2026, uniQure disclosed FDA feedback that its Phase I/II data versus an external control were unlikely to be sufficient as primary evidence, with the agency recommending a new randomized, sham-controlled Phase III trial—creating a negative baseline for sentiment.

This sharp one-day jump also suggests short-covering and fast-money repositioning may have amplified the reaction to the regulatory update.

Sources:

uniQure (Investor Relations), Investing.com, SEC (EDGAR)

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$QURE Insider Trading Activity

$QURE insiders have traded $QURE stock on the open market 26 times in the past 6 months. Of those trades, 0 have been purchases and 26 have been sales.

Here’s a breakdown of recent trading of $QURE stock by insiders over the last 6 months:

ROBERT GUT has made 0 purchases and 7 sales selling 35,891 shares for an estimated $900,968.
MATTHEW C KAPUSTA (CEO, Managing Director) has made 0 purchases and 3 sales selling 61,396 shares for an estimated $770,091.
KYLIE O'KEEFE (Chief Customer & Strat Officer) sold 15,936 shares for an estimated $431,228
CHRISTIAN KLEMT (Chief Financial Officer) has made 0 purchases and 3 sales selling 30,749 shares for an estimated $381,751.
JACK KAYE has made 0 purchases and 3 sales selling 11,028 shares for an estimated $307,626.
JEANNETTE POTTS (Chief Legal Officer) has made 0 purchases and 2 sales selling 11,990 shares for an estimated $116,263.
LEONARD E POST sold 1,993 shares for an estimated $53,930
DAVID D. MEEK sold 1,993 shares for an estimated $53,930
MADHAVAN BALACHANDRAN sold 1,993 shares for an estimated $53,930
JEREMY P. SPRINGHORN sold 1,993 shares for an estimated $53,930
RACHELLE SUZANNE JACQUES sold 1,993 shares for an estimated $53,930
WALID ABI-SAAB (Chief Medical Officer) has made 0 purchases and 2 sales selling 2,468 shares for an estimated $23,837.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive QURE Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$QURE Hedge Fund Activity

We have seen 115 institutional investors add shares of $QURE stock to their portfolio, and 167 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC removed 4,497,128 shares (-72.1%) from their portfolio in Q1 2026, for an estimated $73,528,042
ECOR1 CAPITAL, LLC removed 3,988,971 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $95,456,076
JPMORGAN CHASE & CO added 1,785,275 shares (+155.3%) to their portfolio in Q4 2025, for an estimated $42,721,630
ABERDEEN GROUP PLC added 1,627,746 shares (+44.2%) to their portfolio in Q1 2026, for an estimated $26,613,647
ORBIMED ADVISORS LLC added 1,398,749 shares (+189.7%) to their portfolio in Q1 2026, for an estimated $22,869,546
TWO SEAS CAPITAL LP added 1,300,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $21,255,000
TWO SIGMA INVESTMENTS, LP added 1,224,587 shares (+84.4%) to their portfolio in Q1 2026, for an estimated $20,021,997

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$QURE Price Targets

Multiple analysts have issued price targets for $QURE recently. We have seen 8 analysts offer price targets for $QURE in the last 6 months, with a median target of $35.0.

Here are some recent targets:

Patrick R. Trucchio from HC Wainwright & Co. set a target price of $50.0 on 05/06/2026
Daniil Gataulin from Chardan Capital set a target price of $37.0 on 04/30/2026
Salveen Richter from Goldman Sachs set a target price of $10.0 on 04/20/2026
Eliana Merle from Barclays set a target price of $25.0 on 03/23/2026
Uy Ear from Mizuho set a target price of $35.0 on 03/11/2026
Luca Issi from RBC Capital set a target price of $35.0 on 03/09/2026
Yanan Zhu from Wells Fargo set a target price of $60.0 on 03/09/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.